* Better Therapeutics Inc BTTX.OQ BTTX.O is expected
to report
results on August 11.
* Refinitiv's mean analyst estimate for Better Therapeutics
Inc
is for a loss of 45 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Better
Therapeutics Inc is $15, above its last closing price
of $2.01.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.40 -0.38 -0.41 Missed -6.5
Dec. 31 2022 -0.47 -0.46 -0.71 Missed -55.5
Sep. 30 2021 -1.66 -1.66 -0.03 Beat 98.2
This summary was machine generated August 9 at 18:32 GMT. All
figures in US dollars unless otherwise stated